|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|
||
|
|
|
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
INNOVATE BIOPHARMACEUTICALS is focused on drug development for autoimmune and inflammatory diseases. Its lead product, Larazotide, a tight junction regulator, achieved excellent results in its Phase 2b trial against Celiac Disease. The company has fast track FDA approval for two Phase 3 trials starting in early 2018 and early 2019. Innovate has a second drug in the clinic, INN-108, which completed a successful Phase 1 trial in 2017 against Pediatric Ulcerative Colitis. |
